US-based biotechnology company BrainStorm Cell Therapeutics has partnered with contract development and manufacturing ...

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

A critical appraisal of the state of the prescription medications in the United States ...

FibroFind, a Newcastle University spinout founded in 2019 by Jelena Mann and Lee Borthwick, is set to expand following a ...

Prothena Corporation plc's phase 3 trial failure in AL Amyloidosis was a setback, but Alzheimer's & Parkinson's data could ...

An inexpensive, long-approved HIV drug can improve vision in patients with a blinding complication of diabetes more ...

The FDA cleared an investigational new drug application for AVZO-1418/DB-1418, and a phase 1/2 trial in advanced solid tumors ...

Yet, I assess that Viking Therapeutics’s main growth vector will likely be imputed to its ability to commercialize and ...

Clinical trials refer to medical research that involves testing new treatments on people. The four phases help to ensure the ...

The FDA has cleared Brainstorm to initiate a Phase 3b clinical trial testing NurOwn (debamestrocel) in people with moderate ALS.

Bruce Leuchter, CEO, Neurvati, discusses the indispensable role of patient advocates—particularly in rare and serious disease drug development—in shaping trial design, site selection, and regulatory ...

Organoids, organs-on-a-chip, and machine learning technologies have improved dramatically in recent years, but have they come ...